NCT01659177

A Study of LY2140023 in Healthy Participants

The Effect of Food on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects After Administration of the Commercial Tablet Formulation of LY2140023

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Denovo Biopharma LLC · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The study will evaluate the effect of food on absorption of LY2140023 in blood. This study involves a single dose of 80 mg LY2140023 taken as a tablet by mouth on 2 occasions, once on an empty stomach and once after eating breakfast. There is a minimum 3 day washout between doses. This study will last approximately 16 days not including screening. Screening is required within 30 days prior to the start of the study.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	LY2140023	Administered orally

Timeline

• Start date: 2012-08-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2012-08-07
• Last updated: 2021-08-23

Locations

1 site across 1 country: Switzerland